TY - JOUR
T1 - Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database
T2 - 2007-2009
AU - di Giambenedetto, S.
AU - Prosperi, M.
AU - Fanti, I.
AU - Bruzzone, B.
AU - Paolucci, S.
AU - Penco, G.
AU - Meini, G.
AU - di Biagio, A.
AU - Paolini, E.
AU - Micheli, V.
AU - Meraviglia, P.
AU - Castelli, P.
AU - Corsi, P.
AU - Gonnelli, A.
AU - Fabbiani, M.
AU - Zazzi, M.
AU - de Luca, A.
PY - 2011/9
Y1 - 2011/9
N2 - We analysed trends of human immunodeficiency virus type 1 (HIV-1) drug resistance during 2007-2009 in the Italian national HIV drug resistance database 'ARCA'. Prevalence of resistance in each year was examined on the basis of the presence of major International AIDS Society-2009 mutations. Predictors of resistance were analysed by multivariable logistic regression. Nine hundred and sixty-six patients were selected. Resistance to nucleoside reverse transcriptase inhibitors and protease inhibitors showed a significant decline with respect to previous surveys. Resistance to any class of drug and three drug classes remained stable. Independent predictors of three-class resistance were the number of treatment regimens experienced, prior suboptimal nucleoside reverse transcriptase inhibitor therapy and the current use of ritonavir-boosted protease inhibitors.
AB - We analysed trends of human immunodeficiency virus type 1 (HIV-1) drug resistance during 2007-2009 in the Italian national HIV drug resistance database 'ARCA'. Prevalence of resistance in each year was examined on the basis of the presence of major International AIDS Society-2009 mutations. Predictors of resistance were analysed by multivariable logistic regression. Nine hundred and sixty-six patients were selected. Resistance to nucleoside reverse transcriptase inhibitors and protease inhibitors showed a significant decline with respect to previous surveys. Resistance to any class of drug and three drug classes remained stable. Independent predictors of three-class resistance were the number of treatment regimens experienced, prior suboptimal nucleoside reverse transcriptase inhibitor therapy and the current use of ritonavir-boosted protease inhibitors.
KW - Antiretroviral therapy
KW - Drug resistance mutations
KW - Human immunodeficiency virus-1
UR - http://www.scopus.com/inward/record.url?scp=80051891486&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80051891486&partnerID=8YFLogxK
U2 - 10.1111/j.1469-0691.2011.03563.x
DO - 10.1111/j.1469-0691.2011.03563.x
M3 - Article
C2 - 21635664
AN - SCOPUS:80051891486
VL - 17
SP - 1352
EP - 1355
JO - Clinical Microbiology and Infection
JF - Clinical Microbiology and Infection
SN - 1198-743X
IS - 9
ER -